Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome

Authors:

Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Thomas R. Reich1, Olivier J. Switzeny1, Mirjam Renovanz2, Clemens Sommer3, Bernd Kaina1, Markus Christmann1, Maja T. Tomicic1 1Department of Toxicology, University Medical Center, D-55131 Mainz, Germany 2Department of Neurosurgery, University Medical Center, D-55131 Mainz, Germany 3Department of Neuropathology, University Medical Center, D-55131 Mainz, Germany Correspondence to: Maja T. Tomicic, email: tomicic@uni-mainz.de Markus Christmann, email: mchristm@uni-mainz.de Keywords: high-grade glioma, glioblastoma, temozolomide, XAF1 promoter methylation, IDH1 Received: July 22, 2016 Accepted: January 10, 2017 Published: January 19, 2017

This publication has 57 references indexed in Scilit: